非何杰金氏淋巴瘤市场:KOL的洞察

本报告提供全球非何杰金氏淋巴瘤市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

现在及未来的治疗流程

调查目的

CAR T细胞疗法

• 瀰漫性B大细胞淋巴瘤
  • Yescarta(axicabtagene ciloleucel，Gilead)，Kymriah(tisagenlecleucel，Novartis)，及Breyanzi(lisocabtagene maraleucel，BMS)
• 滤泡型淋巴瘤
  • Yescarta(axicabtagene ciloleucel，Gilead)，Kymriah(tisagenlecleucel，Novartis)，Breyanzi(lisocabtagene maraleucel，BMS)
• 被套细胞淋巴瘤
  • Tecartus(brexucabtagene autoleucel，Gilead)，Breyanzi(lisocabtagene maraleucel，BMS)
• 下一代CAR-T细胞疗法
  • 重要的洞察概要

T细胞结合双特异性抗体(BsAbs)

• 认证核可药/开发平台药物
  • Lunumio(mosunetsuzumabu，Roche)，Epkinly/Tepkinly(epukoritamabu，Genmab/AbbVie)，Columvi(gurofitamabu，Roche)，odoronekutamabu(Regeneron)

抗体药物复合体(ADC)

• 已通过核准医药品
  • Polivy(poratsuzumabubedochin，Roche)
  • Zynlonta(ronkatsukishimabuteshirin，ADC Therapeutics/Sobi)
• 开发平台医药品
  • Adcetris(Brentuximab Vedotin，Seagen/Takeda)

单株抗体(mAb)

• 已通过核准医药品
  • Monjuvi/Minjuvi(tafashitamabu，Incyte/MorphoSys)

Bcl-2抑制剂

• 开发平台医药品
  • venkurekusuta/venkurisuto(Venetoclax，AbbVie/Roche)

BTK抑制剂

• 已通过核准医药品
  • Brukinsa(zanuburuchinibu，BeiGene)，Calquence(akaraburuchinibu，AstraZeneca)，Imbruvica(ibrutinib，Janssen/Pharmacyclics)，Jaypirca(pirutoburuchinibu，Lilly)

今后的治疗趋势

• 重要的洞察摘要

附录

KOL快报

Bispecific antibodies set to disrupt the non-Hodgkin lymphoma treatment algorithm

In what settings do KOLs expect bispecific antibodies such as Roche's Lunsumio and Columvi, and Genmab/AbbVie's Epkinly, to deliver value? What impact will they have on the current treatment algorithm? What factors lead experts to say Lilly's non-covalent BTK inhibitor Jaypirca is a critical advance for patients with mantle cell lymphoma? KOLs critically assess the prospects of launched and pipeline therapies in the complex NHL sector.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

• 18 Sep 2023 KOL Bulletin -- Expert perspective on EC approval of Roche's bispecific Columvi for DLBCL

• 19 Sep 2023 KOL Bulletin -- Views on data from the TRANSCEND FL trial of BMS' CAR-T Breyanzi

Table of Contents

Executive summary (12)

Current and future treatment algorithms

Research objectives (4)

CAR T-cell therapies (31)

• Diffuse large B-cell lymphoma (11)
  • Yescarta (axicabtagene ciloleucel; Gilead), Kymriah (tisagenlecleucel; Novartis) and Breyanzi (lisocabtagene maraleucel; BMS) (11)
• Follicular lymphoma (8)
  • Yescarta (axicabtagene ciloleucel; Gilead), Kymriah (tisagenlecleucel; Novartis) and Breyanzi (lisocabtagene maraleucel; BMS) (8)
• Mantle cell lymphoma (7)
  • Tecartus (brexucabtagene autoleucel; Gilead) and Breyanzi (lisocabtagene maraleucel; BMS) (7)
• Next-generation CAR T-cell therapies (5)
  • Key insights summary (5)

T cell-engaging bispecific antibodies (BsAbs) (21)

• Approved/pipeline drugs (21)
  • Lunsumio (mosunetuzumab; Roche), Epkinly/Tepkinly (epcoritamab; Genmab/AbbVie), Columvi (glofitamab; Roche) and odronextamab (Regeneron) (21)

Antibody-drug conjugates (ADCs) (24)

• Approved drugs (17)
  • Polivy (polatuzumab vedotin; Roche) (9)
  • Zynlonta (loncastuximab tesirine; ADC Therapeutics/Sobi) (8)
• Pipeline drugs (7)
  • Adcetris (brentuximab vedotin; Seagen/Takeda) (7)

Monoclonal antibodies (mAbs) (8)

• Approved drugs (8)
  • Monjuvi/Minjuvi (tafasitamab; Incyte/MorphoSys) (8)

Bcl-2 inhibitors (6)

• Pipeline drugs (6)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (6)

BTK inhibitors (13)

• Approved drugs (13)
  • Brukinsa (zanubrutinib; BeiGene), Calquence (acalabrutinib; AstraZeneca), Imbruvica (ibrutinib; Janssen/Pharmacyclics) and Jaypirca (pirtobrutinib; Lilly) (13)

Future treatment trends (4)

• Key insights summary (4)

Appendix (4)

• KOL details (4)
  • KOLs from the US (1)
  • KOLs from Europe (2)

KOL Bulletins (3)